Antihemophilic Factor (Human), Ko├áte®-DVI, is a sterile, stable, purified, dried concentrate of human Antihemophilic Factor (AHF, factor VIII, AHG) which has been treated with tri-n-butyl phosphate (TNBP) and polysorbate 80 and heated in lyophilized form in the final container at 80░C for 72 hours. Ko├áte-DVI is intended for use in therapy of classical hemophilia (hemophilia A).
Ko├áte-DVI is indicated for the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor VIII. Ko├áte-DVI provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
Ko├áte-DVI contains naturally occurring von Willebrand's factor, which is co-purified as part of the manufacturing process.
Ko├áte-DVI has not been investigated for efficacy in the treatment of von Willebrand's disease, and hence is not approved for such usage.
Published Studies Related to Koate-DVI (Antihemophilic Factor)
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. [2000.06]
To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step...
Clinical Trials Related to Koate-DVI (Antihemophilic Factor)
Russian Kogenate Pediatric Study [Completed]
Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha« In Subjects With Hemophilia A [Completed]
Study Evaluating The Safety Of Xyntha In Usual Care Settings [Terminated]
The purpose of this study is to collect safety information associated with the use of Xyntha
in a usual care setting. Upon meeting eligibility criteria, patients will be required to
have approximately 5 study visits over a 2 year period. Procedures completed throughout the
study include collection of vital signs, physical exams, and laboratory assessments.
Patients will be required to complete an infusion log for each Xyntha infusion.
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS) [Recruiting]
This is a Post-Authorization Safety Surveillance (PASS) study designed to collect data on
the safety and effectiveness of ADVATE reconstituted in 2 mL Sterile water for injection
(SWFI) during routine clinical practice in children until 12 years of age. This surveillance
study is a post-licensure commitment for ADVATE reconstituted in 2 mL SWFI.
Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A [Not yet recruiting]
Hemophilia A is an X-linked recessive, congenital bleeding disorder caused by deficient or
defective coagulation factor VIII (FVIII). Prophylaxis is recommended as the standard of
care for boys with severe haemophilia by WHO and World Federation Of Hemophilia (WFH). The
efficacy and safety of prophylaxis in preventing bleeds and arthropathy in patients with
hemophilia has been confirmed in well-designed clinical studies. To keep the factor level
above 1%, the standard dosage for patients with severe hemophilia A is 20-40 Units
/kg/infusion (average 30 Units /kg) every other day or three times a week. This dosage has a
very high consumption of factor, up to 5000-6000 international unit (IU)/kg/year. The high
consumption of factor and cost present a major barrier to use the standard prophylaxis in
many countries particularly in the developing world.
In China the majority of boys with severe hemophilia A can only pay for on-demand treatment
or low-dose prophylaxis. Ao after the affordability of patients was solved and many patients
will get more chance to receive standard prophylaxis.
This study is designed to evaluate the Annual Bleeding rate (ABR), joint health outcomes and
QoL outcomes in subjects using ADVATE(Recombinant Human Coagulation Factor VIII for
injection) standard prophylaxis under the conditions of routine practice.
Page last updated: 2006-01-31